Abstract Search

ea0089t7 | Trials In Progress | NANETS2022

Methodology of the SORENTO Clinical Trial: Assessing Efficacy and Safety of High Exposure Octreotide Subcutaneous Depot in Patients with GEP-NET

Singh, MD Simron , Capdevila, MD, PhD Jaume , Ang Chan, MD Jennifer , de Herder, MD Wouter , Ferone, MD, PhD Diego , Halperin, MD Daniel , Mailman, MBA Josh , Hellstrom, MSc Lisa , Svedberg, MSc, MBA Agneta , Tiberg, PhD Fredrik

Background: Somatostatin analogues (SSAs) are first-line standard of care therapies for gastroenteropancreatic neuroendocrine tumors (GEP-NET), showing efficacy in tumor/symptom control with an established safety profile. Yet, disease progression may occur despite standard-dose SSA treatment, requiring more aggressive and toxic therapies. Retrospective/non-randomized data suggest higher-dose SSAs may benefit patients with GEP-NET who do not respond to standard-dose treatment a...

0 shares

Endocrine Abstracts

Methodology of the SORENTO Clinical Trial: Assessing Efficacy and Safety of High Exposure Octreotide Subcutaneous Depot in Patients with GEP-NET

BiosciAbstracts